IBI354 — Investigational Agent
Antibody-Drug Conjugate · Phase 3 · Innovent Biologics
Mechanism of Action
An anti-HER2 antibody conjugated to a novel topoisomerase I inhibitor payload via a cleavable linker, enabling targeted delivery and bystander cytotoxicity in HER2-expressing tumors including ovarian and breast cancers.
Investigational Indications
- Platinum-resistant ovarian/fallopian tube/primary peritoneal cancer
- HER2-positive metastatic breast cancer
- HER2-expressing gastrointestinal tumors